Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.

ABSTRACT:

Introduction

Type 2 diabetes mellitus (T2DM) is a complex disease in which multiple organs and hormones contribute to the pathogenesis of disease. The intestinal hormone, glucagon-like peptide-1 (GLP-1), secreted in response to nutrient ingestion, increases insulin secretion from pancreatic β-cells and reduces glucagon secretion from pancreatic α-cells. GLP-1 is inactivated by the dipeptidyl peptidase-4 (DPP-4) enzyme. Saxagliptin is a DPP-4 inhibitor that prevents the degradation of endogenous GLP-1 and prolongs its actions on insulin and glucagon secretion. This article reviews the efficacy and safety of saxagliptin in patients with T2DM.

Methods

A PubMed literature search was conducted to identify relevant, peer-reviewed saxagliptin clinical trial articles published betwe

SUBMITTER: Jain R 

PROVIDER: S-EPMC4662714 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature